Page 8 - Two Phase News Today

/PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) announced today detailed results from two pivotal Phase 3 trials (BRAVE-AA1 and...

GuruFocus Article or News written by Marketwired and the topic is about:

AbbVie Showcases the Depth of its Rheumatology Portfolio with New Data Presented at the EULAR 2021 Virtual Congress of Rheumatology ABBVie today announced that it will present new data from a total of 41 abstracts covering its portfolio of immunology assets, including RINVOQ ® SKYRIZI ® HUMIRA ® and its pipeline across multiple rheumatic diseases at the EULAR 2021 Virtual Congress of Rheumatology, to be held virtually June 2-5 . Among the data presented will be new three-year and one-year ef...

Share this article Share this article SUZHOU, China, May 19, 2021 /PRNewswire/ -- Transcenta Holding Limited ("Transcenta"), a global biotherapeutics company with fully-integrated capabilities in discovery, development and manufacturing of antibody-based therapeutics, announced that the updated Phase I clinical study (NCT04272944) data on the safety and efficacy of MSB2311, a pH-dependent PD-L1 antibody, in Chinese patients with advanced solid tumors and hematological malignancies have been pre...

Harnessing The Power Of AI In MS Diagnosis, Monitoring, And Treatment By Andrew Thomson, Logan Wright, and Lev Gerlovin, Life Sciences Practice, CRA Applications of artificial intelligence (AI) are rapidly expanding in healthcare, including the handling of administrative logistics at hospitals, assessment of patient health data, and analysis of novel molecules in drug discovery. A prime example of the future potential of AI is in revolutionizing the way we diagnose, monitor, and treat multiple ...

Share this article SPRING HOUSE, Pa., March 16, 2021 /PRNewswire/ --  The Janssen Pharmaceutical Companies of Johnson & Johnson today announced long-term data from the Phase 3 DISCOVER-2 a study showing that the skin clearance, joint symptom relief, and safety of TREMFYA ® (guselkumab) previously demonstrated through 24 weeks and one year (Week 52) in adults with active psoriatic arthritis (PsA) continued through two years (Week 112). 1,2 These findings also confirmed that the robust efficacy...

Biktarvy® Demonstrates High Efficacy and Durable Viral Suppression in Treatment-Naïve Adults in Four-Year Data Presented at CROI 98% of Treatment-Naïve Patients Achieved and Maintained Undetectable Viral Load with Biktarvy Through Four Years in the Open-Label Extension Phase of Two Phase 3 Studies – – Treatment-Naïve Adults Reached and Maintained Undetectable Viral Load with Biktarvy for Certain Transmitted-Drug Resistance and with No Treatment-Emergent Resistance Through 144 Weeks – ...

Search jobs U.S. FDA Accepts Merck’s Gefapixant New Drug Application for Review Application for Orally Administered Selective P2X3 Receptor Antagonist Based on Findings from Two Phase 3 Trials in Patients with Refractory or Unexplained Chronic Cough Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company’s New Drug Application (NDA) for gefapixant, an i...

The Fantastic Four is one of Marvel's most beloved superhero groups. Many fans hope they can one day become as mainstream as the Avengers.

German police. he asked the loan and theres no indication of islamic extremist motive, but investigators are looking into what they call all possibilities in that crash. >> coming up, facebook founder mark zuckerberg two-phase members this week. they may be ready to underfund him over breaches of personal information. well talk to house committee members who are ready to ask very tough russians. our panel debates president trumps high-stakes standoff with china. and what it means for millions of...